In addition to inhibiting the TGF-β signaling pathway, targeting the chemokine receptor CCR2, which is involved in the recruitment of N2 neutrophils, may prevent their accumulation in the TME, reducing their tumor-promoting effects and enhancing the effectiveness of other treatments[93,94]. The gene discussed is TGFB1; the disease is neoplasm.